Back to first-pass browser

First-pass extracted concept

asialo-EPO

Candidate: toolkit item1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

asialoerythropoietin

Extracted Explainers

What the tool is doing

Asialo-EPO is described as one of four engineered EPO derivatives considered for phase-targeted neuroprotection in traumatic brain injury. It is included because the review says these derivatives decouple cytoprotection from red-cell stimulation.

Source 1DOIPubMed

What problem it solves

It is positioned as a way to retain protective signaling while reducing the erythropoietic liabilities associated with recombinant EPO.

Source 1DOIPubMed

What it does not solve

The abstract does not establish definitive clinical benefit or optimal use conditions in TBI. Further controlled studies are required according to the review.

Source 1DOIPubMed

Alternatives

The abstract names carbamylated EPO, darbepoetin alfa, and helix-B surface peptide/cibinetide as alternative engineered derivatives.

Source 1DOIPubMed

Evidence Snippets

This review integrates structural biology, pharmacology and translational data on four engineered EPO derivatives-carbamylated EPO, asialo-EPO, darbepoetin alfa and the helix-B surface peptide (HBSP/cibinetide)-that decouple cytoprotection from red-cell stimulation.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1engineering strategysupports2025Source 1DOIPubMed

Carbamylated EPO, asialo-EPO, darbepoetin alfa, and helix-B surface peptide/cibinetide are engineered EPO derivatives intended to decouple cytoprotection from red-cell stimulation.

Claim 2signaling biassupports2025Source 1DOIPubMed

Carbamylation, desialylation, hyper-glycosylation, and helix truncation are described as modifications that bias EPOR signaling toward PI3K-AKT and away from JAK2-STAT5.

Claim 3timing strategysupports2025Source 1DOIPubMed

The review matches each engineered EPO derivative to an optimal injury window in traumatic brain injury.